Solid Earnings May Not Tell The Whole Story For Lushang Freda PharmaceuticalLtd (SHSE:600223)
Solid Earnings May Not Tell The Whole Story For Lushang Freda PharmaceuticalLtd (SHSE:600223)
The stock price didn't jump after Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) posted decent earnings last week. We think that investors might be worried about some concerning underlying factors.
上周,福瑞达医药股份有限公司(SHSE:600223)发布了可观的收益,但股价并未上涨。我们认为投资者可能担心一些令人关注的潜在因素。
How Do Unusual Items Influence Profit?
非常规项目如何影响利润?
For anyone who wants to understand Lushang Freda PharmaceuticalLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥26m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Lushang Freda PharmaceuticalLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
对于任何想要了解福瑞达医药有限公司超越法定数字的利润的人来说,值得注意的是,在过去十二个月中,法定利润中获得了2600万人民币的飞凡项目收益。尽管盈利增加总是好事,但来自飞凡项目的大量贡献有时会减弱我们的热情。当我们分析全球绝大多数上市公司时,我们发现重大的飞凡项目往往不会重复出现。这正如您所期望的那样,因为这些提振被描述为“飞凡”。如果福瑞达医药有限公司看不到这种贡献再现,那么其他一切相等的情况下,我们预计其利润会在今年下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。
Our Take On Lushang Freda PharmaceuticalLtd's Profit Performance
我们对福瑞达医药有限公司的盈利表现看法
Arguably, Lushang Freda PharmaceuticalLtd's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Lushang Freda PharmaceuticalLtd's statutory profits are better than its underlying earnings power. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - Lushang Freda PharmaceuticalLtd has 1 warning sign we think you should be aware of.
可以说,福瑞达制药有限公司的法定收入受到提高利润的飞凡项目扭曲。正因为如此,我们认为福瑞达制药有限公司的法定利润可能优于其潜在盈利能力。但令人高兴的消息是,尽管我们承认必须超越法定数字,但这些数字仍在改善,EPS在过去一年增长得非常快。当然,在分析其盈利方面时,我们只是触及了表面;人们还可以考虑利润率、预测增长和投资回报率,以及其他因素。考虑到这一点,除非我们充分了解风险,否则我们不会考虑投资股票。例如 - 福瑞达制药有限公司有一个警告标志,我们认为您应该意识到。
Today we've zoomed in on a single data point to better understand the nature of Lushang Freda PharmaceuticalLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天,我们把焦点放在一个单一数据点上,以更好地了解福瑞达制药有限公司利润的性质。但有许多其他方法可以帮助你了解一家公司。有些人认为高净资产回报率是一个高质量企业的良好标志。也许需要您做一些研究,您可能会发现这个免费的公司收藏具有较高净资产回报率,或者这个拥有重要内部持股的股票清单很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。